Company
Solid Biosciences
Focused on advancing genetic medicines for neuromuscular and cardiac diseases
Also known as Solid Biosciences Inc.
- Business model
- B2B
- Legal name
- Solid Biosciences Inc.
- solidbio.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases.
Funding snapshot
- Total raised
- $109MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $9.2M2022-12-02
Funding rounds
- Round, 2022
- $9.2M2022-12-02, SEC form D sold, 13 investors
- Round, 2020
- $40M2020-10-22, SEC form D sold, 1 investor
- Round, 2019
- $60M2019-07-30, SEC form D sold, 15 investors
Products
- Web
- SGT-003
- Web
- SGT-212
- Web
- SGT-501
- Web
- SGT-601
Loading relationship preview